EU Official Disappointed That Pediatric Development Still Seen As Just A 'Regulatory Requirement'
Executive Summary
Weeks before an important report is due on the impact of the EU Paediatric Regulation, a senior European Commission official shares his personal reflections on how some simple concepts in the legislation have not translated into the real world as intended.
You may also be interested in...
European Commission Gives Sneak Preview Of Hotly-Awaited Pediatrics Report
The European Commission’s soon-to-be-published report on the EU Paediatric Regulation could lead to legislative changes that address some of the many problems pharma companies have with the 10-year old rules.
EMA May Clash With Ethics Committees If It Asks For Earlier Neonatal Trials
As the European Medicines Agency starts to address the findings of a report that questions the wisdom of granting lengthy deferrals for neonatal studies, an industry expert warns that by requiring such studies to be initiated earlier, the agency may come into conflict with ethics committees.
EMA Reviews Experience With Deferring PIPs: Will it Result In Earlier Pediatric Trials?
The European Medicines Agency is examining its current experience with granting deferrals for studies mandated under the EU Paediatric Regulation, and is re-considering when it is most appropriate to grant deferrals for neonatal studies.